Contraceptive Counselling: Impact on Awareness of the Risk of Unwanted Pregnancy and on the Appeal of Contraception (CMC)
Le Conseil Minimal Autour de la Contraception : Quel Impact Sur la Prise de Conscience du Risque de Grossesse Non désirée et Sur l'Attrait à la Contraception
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Saint-Philippe, Réunion, 97442
- Cabinet de médecine générale
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
On the basis of 30 participating GPs, the estimation of the number of inclusions is 400 women, which seems sufficient for this study.
The desired number of inclusions is 45 women/month (400 women over 9 months).
Description
Inclusion Criteria:
- Women from 18 to 50 years old
- Consulting in a general practice in Reunion Island
- French or Creole speaking
- Not having any contraceptive means
- Having sexual intercourse
- Not having any desire to become pregnant within the year
- Collection of non-opposition
Exclusion Criteria:
- Consultation for a desire or follow-up of a pregnancy
- Consultation for an abortion
- Consultation for a contraceptive method
- Known infertility
- Inability to answer the telephone (hearing impaired, mute)
- Severe cognitive disorder (mental retardation, dementia, active psychosis)
- Women under guardianship or curatorship
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Impact of a minimal councelling regarding the contraception awareness of risk of unwanted pregnancy
Time Frame: between Day 1 and Month 1
|
Change of Proportion of women with no contraception and having sexual relations without a desire of pregnancy
|
between Day 1 and Month 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sébastien LERUSTE, MD, Universite de La Reunion
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2021/CHU/34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.